Accufix
Accufix has developed the Accu-Joint® hemi implant system, an FDA-approved solution for metatarsophalangeal (MTP) joint disorders that resurfaces the bone end without resection, allowing for natural joint motion. This system enables patients to regain mobility and functionality quickly, as it is weight-bearing from day one, facilitating a faster recovery compared to traditional fusion methods.
- Biotechnology
- Healthcare Technology
- Medical Devices
Funding
Raised to date
$5.3MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Metatarsophalangeal (MTP) joint disorders can cause significant pain and limited mobility, impacting a patient's ability to perform daily activities and maintain an active lifestyle. Traditional treatments, such as fusion, often restrict joint movement, hindering natural motion and functionality.
Solution
Accufix has developed the Accu-Joint® hemi implant system, an FDA-approved solution designed to address MTP joint disorders by resurfacing the bone end without resection. This approach allows for the preservation of natural joint motion and enables patients to regain mobility and functionality. The Accu-Joint® implant facilitates a faster recovery compared to traditional fusion methods, as it is weight-bearing from day one, allowing patients to return to their feet and resume activities sooner. The patented two-stage reamer ensures precise resurfacing of the bone end, optimizing implant fit and joint mechanics.
Target Audience
The primary users are surgeons specializing in foot and ankle procedures, specifically those treating patients with MTP joint disorders.
Features
- Patented 2-stage reamer resurfaces the bone end without resection.
- Hemi-implant design preserves natural joint motion.
- Weight-bearing from day one to facilitate faster recovery.